Supplementary Figure 10: In vivo delivery of the optogenetic LTD-inducing protocol reduced alcohol-seeking behavior in an endocannabinoid manner.

(a) In vivo delivery of LTD-inducing protocol (oHFS+oPSD+MK801+raclopride) in the DMS produced a long-lasting decrease in alcohol deliveries. F_(5,38) = 4.27, P = 0.0035. *P < 0.05, **P < 0.01 vs. baseline (BL). n = 9 rats. (b-d) In vivo oHFS stimulation in presence of the cocktail (MK801+raclopride) did not alter lever presses (b; F_(4,27) = 0.50, P = 0.74), alcohol deliveries (c; F_(4,27) = 0.32, P = 0.86), or alcohol intake (d; F_(4,27) = 0.53, P = 0.72). n = 9 rats. (e-g) Administration of the cocktail (MK801+raclopride) did not affect lever presses (e; F_(4,21) = 2.12, P = 0.11), alcohol deliveries (f; F_(4,21) = 1.43, P = 0.26), or alcohol intake (g; F_(4,21) = 0.42, P = 0.79). n = 8 rats. (h-i) In vivo optogenetic delivery of the LTD-inducing protocol (oHFS+oPSD+MK801+raclopride) in the presence of AM251 failed to alter alcohol deliveries (h; F_(4,31) = 0.46, P = 0.76), or alcohol intake (i; F_(4,32) = 0.42, P = 0.79). n = 9 rats. (j-l) Systemic administration of AM251 (0.3 mg/kg) did not affect lever presses (j; F_(2,17) = 0.33, P = 0.73), alcohol deliveries (k; F_(2,17) = 1.05, P = 0.37), or alcohol intake (l; F_(2,17) = 2.31, P = 0.13), as compared to before (baseline, BL) and after (Post) treatment. n = 10 rats. One-way RM ANOVA for all figures. Data are presented as mean ± s.e.m.